EPO published patent EP3826615A1 for Taiwan Liposome Company covering sustained-release pharmaceutical compositions for dementia treatment using liposomal drug delivery technology. The patent application (filed under IPC classification A61P 25/28 for nervous system diseases) names four inventors and designates 31 states including all EU member states, UK, Switzerland, Norway, and Turkey. Publication date is March 25, 2026.\n\nThis is a routine patent publication notice rather than a regulatory action creating compliance obligations. Companies developing dementia therapeutics or liposomal drug delivery systems should review the patent claims to assess freedom-to-operate. No compliance deadlines or penalties are associated with this publication. Entities with competing applications or existing products in this space may wish to seek legal counsel regarding potential overlap.